In conclusion, based on relatively large sample size and longer follow-up time, our results showed that the combination of anti-BCMA and humanized anti-CD19 CAR-T cells induced durable response in R/R MM patients with a safe long-term profile. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.